

Follicular Lymphoma

**Untreated Follicular Lymphoma Treated With ObinituzumAb in a Non-interventional Study (URBAN)**

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT04034056 ML41215

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

To evaluate the effectiveness and safety of obinituzumab in clinical routine in 1L FL measured by the % of relapse within 24 months from start of therapy.

**Hoffmann-La Roche**  
Sponsor

**N/A**  
Phase

---

**NCT04034056 ML41215**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---